Mrugala, Maciej M.
Shi, Wenyin
Iwomoto, Fabio
Lukas, Rimas V.
Palmer, Joshua D.
Suh, John H.
Glas, Martin
Funding for this research was provided by:
Novocure Inc
Article History
Received: 6 February 2024
Accepted: 15 April 2024
First Online: 29 June 2024
Declarations
:
: Maciej M Mrugala reports consultant fees from Alexion, Biocept, and Merck. Wenyin Shi reported grants/research support from Novocure Inc, Brainlab AG, and Regeneron Pharmaceuticals; and work as a consultant/independent contractor for Novocure Inc, Varian Medical Systems Inc, and Brainlab AG & Dohme Corp; role as an advisory/board member and work as a consultant/independent contractor with Vascular Biogenics Ltd (VBL) and ViruCure Therapeutics; and role on speaker bureaus and honorarium from Takeda and AstraZeneca. Fabio Iwomoto reports consultant fees from AbbVie, Alexion Pharmaceuticals, Gennao Bio, Guidepoint Global, Kiyatec, Massive Bio, Medtronic, Merck, MimiVax, Novocure, PPD, Regeneron, Tocagen, and Xcures; research funding from Bristol-Myers Squibb, Celldex, FORMA Therapeutics, Merck, Northwest Biotherapeutics, Novocure, Sapience Therapeutics and Tocagen; travel and accommodation expenses from Oncoceutics. Rimas V Lukas reported grants/research support from NCI P50CA221747, BrainUp grant 2136, Bristol-Myers Squibb (drug support only for IIT); role as an advisory/ board member for Merck, Novocure, Cardinal Health, and AstraZeneca; work on a speaker bureau for Novocure Inc and Merck; honorarium from MedLink Neurology, EBSCO Publishing, and Elsevier. Joshua D Palmer reports consultant fees from Varian Medical Systems, ICOTEC and Novocure; research funding from NIH and Genentech. John H Suh reports consultant fees from Novocure and Philips; provides consultancy services for Neutron Therapeutics and EmpNia, and travel fees from Novocure Inc. Martin Glas reported work as a consultant/independent contractor with Roche Pharma, Novartis, AbbVie Inc, Novocure Inc, Servier, Seagen and Daiichi-Sankyo; honorarium from Novartis, UCB Inc, TEVA Pharmaceuticals, Bayer Corp, Novocure Inc, Medac, Merck Sharp & Dohme Corp, and Kyowa Kirin Group; and travel fees from Novocure Inc and Medac.